Madrigal Pharmaceuticals to Announce First Quarter 2022 Financial Results and Provide Clinical and Business Updates on May 9

Rhea-AI Summary

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) will announce its Q1 2022 financial results on May 9, 2022, at 6:30 am ET. The announcement will include updates on their clinical programs and further results from the Phase 3 MAESTRO-NAFLD-1 study. Following the press release, a conference call is scheduled for the same day at 8:00 am ET. Investors can access the live webcast on Madrigal's website, where an archived version will be available post-event. Madrigal focuses on novel therapies for non-alcoholic steatohepatitis (NASH), with its lead candidate, resmetirom, in Phase 3 trials.

Positive

• Upcoming Q1 2022 financial results announcement on May 9, 2022.
• Progress in clinical development of resmetirom, a potential treatment for NASH.

Negative

• None.

CONSHOHOCKEN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), will report its first quarter 2022 financial results on Monday, May 9, 2022 and provide business and clinical program updates with some additional results from the Phase 3 MAESTRO-NAFLD-1 study.

The schedule for the press release and conference call/webcast is as follows:

Press Release:	May 9th, 2022 at 6:30 am ET
Conference Call:	May 9th, 2022 at 8:00 am ET
• Domestic Dial-In Number:	(833) 660-2754
• International Dial-In Number:	(409) 350-3497
• Conference ID Number:	9765409

To access the live webcast of the call please visit the Investor Events and Presentations section of Madrigal’s website or click here. An archived webcast will be available on the Madrigal website after the event.

About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), a liver disease with high unmet medical need. Madrigal’s lead candidate, resmetirom, is a once daily, oral, thyroid hormone receptor (THR)-β selective agonist that is designed to target key underlying causes of NASH in the liver. Resmetirom is currently being evaluated in two Phase 3 clinical studies, MAESTRO-NASH and MAESTRO-NAFLD-1, designed to demonstrate multiple benefits in patients with NASH. For more information, visit www.madrigalpharma.com.

Investor Contact
Alex Howarth, Madrigal Pharmaceuticals, Inc., IR@madrigalpharma.com

Media Contact
Christopher Frates, Madrigal Pharmaceuticals, Inc., media@madrigalpharma.com

FAQ

When will Madrigal Pharmaceuticals report its Q1 2022 financial results?

Madrigal Pharmaceuticals will report its Q1 2022 financial results on May 9, 2022, at 6:30 am ET.

What is the significance of the Phase 3 MAESTRO-NAFLD-1 study?

The Phase 3 MAESTRO-NAFLD-1 study is crucial for evaluating the efficacy of Madrigal's lead candidate, resmetirom, in treating NASH.

How can I access the Madrigal Pharmaceuticals conference call?

You can access the Madrigal Pharmaceuticals conference call on May 9, 2022, at 8:00 am ET via their website or by phone.

What is resmetirom and what condition does it target?

Resmetirom is an oral thyroid hormone receptor (THR)-β selective agonist developed by Madrigal for treating non-alcoholic steatohepatitis (NASH).